Found 17 clinical trials
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
- 204 views
- 08 Nov, 2020
- 1 location
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors
- 184 views
- 25 Mar, 2021
- 1 location
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
- 246 views
- 25 Mar, 2021
- 1 location
Natalizumab and Chronic Inflammation
In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages
- 0 views
- 25 Mar, 2022
- 1 location
Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab
) before and after starting Natalizumab therapy and (2) Compare BeCare-derived with clinically-derived performance metrics.
- 0 views
- 09 Jan, 2022
- 1 location
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing
- 0 views
- 26 Mar, 2022
- 1 location
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
The purpose of this study is to evaluate if monthly natalizumab, initiated after delivery, is effective in preventing postpartum relapses.
- 22 views
- 26 Jan, 2021
- 1 location
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis (NEXT-MS)
Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab infusions
- 7 views
- 24 Feb, 2022
- 17 locations
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy
The purpose of this study is to assess the efficacy of autologous PBSCT versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or
- 120 views
- 08 Nov, 2020
- 1 location
Inflammatory Response In Schizophrenia (IRIS)
schizophrenia, or whether this is a secondary phenomenon of no pathophysiological significance. The investigators therefore plan to test the effect of a monoclonal antibody (natalizumab) on psychotic symptoms
- 0 views
- 21 Apr, 2022
- 1 location
- 1
- 2